Stock listing

Atyr Pharma, Inc.

Selected listing: A2PM86 · LS · EUR · DE

Atyr Pharma, Inc. (Lang & Schwarz: A2PM86), Health Technology. Latest release Sep 24, 2026: ATyr Pharma Announces Alignment with FDA on Phase 3 Study…

A2PM86:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2PM86
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Atyr Pharma, Inc.

ATyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

September 24, 2026

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

September 1, 2026

ATyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

August 10, 2026

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

July 15, 2026

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

May 14, 2026

All Atyr Pharma, Inc. news →

Research Atyr Pharma, Inc.

Atyr Pharma, Inc. company profile

View the public company page for Atyr Pharma, Inc. on 6ix.

Atyr Pharma, Inc. news

Read company news and market updates connected to Atyr Pharma, Inc..

Atyr Pharma, Inc. investor events

Find investor webinars, events, and replay context for Atyr Pharma, Inc..